Straits Times Index
3,320.45 -1.63 (-0.05%) Nikkei
39,161.65 +123.49 (+0.32%) Hang Seng
18,126.62 -240.33 (-1.31%) FTSE 100
8,228.48 -16.89 (-0.20%) Bitcoin USD
69,364.82 -280.56 (-0.40%) CMC Crypto 200
1,439.38 -7.29 (-0.50%)
Lexeo Therapeutics, Inc. (LXEO)
After hours:
| Previous close | 17.25 |
| Open | 17.11 |
| Bid | 18.67 x 100 |
| Ask | 18.96 x 100 |
| Day's range | 16.79 - 18.93 |
| 52-week range | 9.00 - 22.33 |
| Volume | |
| Avg. volume | 146,747 |
| Market cap | 617.065M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 21.50 |
ZacksWhat Makes Lexeo Therapeutics, Inc. (LXEO) a New Buy Stock
Lexeo Therapeutics, Inc. (LXEO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ZacksWall Street Analysts Think Lexeo Therapeutics, Inc. (LXEO) Could Surge 57.82%: Read This Before Placing a Bet
The mean of analysts' price targets for Lexeo Therapeutics, Inc. (LXEO) points to a 57.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
GlobeNewswireLexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
Closed an oversubscribed $95 million equity financing in March with Q1 2024 cash balance of $195.1 million at quarter-end, expected to provide runway into 2027 Completed in-license agreement with Cornell University for intellectual property rights, including current and future clinical data from an ongoing investigator-initiated trial of AAVrh.10hFXN (LX2006) to support regulatory discussions Interim readout of combined data set of LX2006 at multiple doses anticipated in mid-2024; Lexeo expects
